CoChat

Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial

Reichel, Felix Friedrich, Michalakis, Stylianos, Wilhelm, Barbara, Zobor, Ditta, Muehlfriedel, Regine, Kohl, Susanne, Weisschuh, Nicole, Sothilingam, Vithiyanjali, Kuehlewein, Laura, Kahle, Nadine, Seitz, Immanuel, Paquet-Durand, Francois, Tsang, Stephen H, Martus, Peter, Peters, Tobias, Seeliger, Mathias, Bartz-Schmidt, Karl Ulrich, Ueffing, Marius, Zrenner, Eberhard, Biel, Martin, Wissinger, Bernd, Fischer, Dominik · 2022 · British Journal of Ophthalmology
Cited by 72

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: To determine long-term safety and efficacy outcomes of a subretinal gene therapy for CNGA3-associated achromatopsia. We present data from an open-label, nonrandomised controlled trial (NCT02610582). Methods: Details of the study design have been previously described. Briefly, nine patients were treated in three escalating dose groups with subretinal AAV8.CNGA3 gene therapy between November 2015 and October 2016. After the first year, patients were seen on a yearly basis. Safety assessment constituted the primary endpoint. On a secondary level, multiple functional tests were carried out to determine efficacy of the therapy. Results: No adverse or serious adverse events deemed related to the study drug occurred after year 1. Safety of the therapy, as the primary endpoint of this trial, can, therefore, be confirmed. The functional benefits that were noted in the treated eye at year 1 were persistent throughout the following visits at years 2 and 3. While functional improvement in the treated eye reached statistical significance for some secondary endpoints, for most endpoints, this was not the case when the treated eye was compared with the untreated fellow eye. Conclusion: The results demonstrate a very good safety profile of the therapy even at the highest dose administered. The small sample size limits the statistical power of efficacy analyses. However, trial results inform on the most promising design and endpoints for future clinical trials. Such trials have to determine whether treatment of younger patients results in greater functional gains by avoiding amblyopia as a potential limiting factor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2021-319067

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 72

Metadata

Authors
Reichel, F. F., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Sothilingam, V., Kuehlewein, L., Kahle, N., Seitz, I., Paquet-Durand, F., Tsang, S. H., Martus, P., Peters, T., Seeliger, M., Bartz-Schmidt, K. U., Ueffing, M., Zrenner, E., Biel, M., Wissinger, B., & Fischer, D.
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2021-05-18
Volume
106
Issue
11
Pages
1567-1572
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W3160651649
Cited by
72
References
6
FWCI
3.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial. https://app.cochat.ai/papers/10.1136/bjophthalmol-2021-319067
The paper
Reichel, F. F., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Sothilingam, V., Kuehlewein, L., Kahle, N., Seitz, I., Paquet-Durand, F., Tsang, S. H., Martus, P., Peters, T., Seeliger, M., Bartz-Schmidt, K. U., Ueffing, M., Zrenner, E., . . . Fischer, D. (2022). Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2021-319067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.